モキシフロキサシン (Synonyms: Moxifloxacin; BAY 12-8039 (free base))

Name: Moxifloxacin
Brand: MedChemExpress
SKU: HY-66011A
Rating: 5.0 (23 reviews)

製品番号: HY-66011A 純度: 99.75%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

モキシフロキサシン 構造式

CAS 番号 : 151096-09-2

容量	価格（税別）	在庫状況	数量
100 mg	$50	在庫あり	Estimated Time of Arrival: December 31
500 mg	$110	在庫あり	Estimated Time of Arrival: December 31
1 g	$165	在庫あり	Estimated Time of Arrival: December 31
5 g		お問い合わせ
10 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 23 publication(s) in Google Scholar

Other Forms of Moxifloxacin:

Moxifloxacin-d₄ 在庫あり
Moxifloxacin-¹³C,d₃ hydrochloride 在庫あり
Moxifloxacin-d₄ hydrochloride 在庫あり
(Rac)-Moxifloxacin 在庫あり
rac cis-Moxifloxacin-d₄ hydrochloride 在庫あり
Moxifloxacin Hydrochloride 在庫あり
Moxifloxacin hydrochloride monohydrate 在庫あり
Moxifloxacin (Standard) 在庫あり
Moxifloxacin-d₃ hydrochloride お問い合わせ
Moxifloxacin-d₃-1 hydrochloride お問い合わせ
Moxifloxacin-d₅ お問い合わせ
(Rac)-Moxifloxacin-d₄ お問い合わせ

顧客検証

Antibiotic アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

Quinolone

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	173 μM Compound: moxifloxacin	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	168.9 μM Compound: Moxifloxacin	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEp-2	CC₅₀	> 100 μM Compound: MXF	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HEp-2	CC₅₀	> 100 μM Compound: MXF	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	> 100 μM Compound: MXF	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HEp-2	CC₅₀	> 100 μM Compound: moxifloxacin	Cytotoxicity against Hep2 cell line Cytotoxicity against Hep2 cell line	[PMID: 16337789]
HEp-2	CC₅₀	> 100 μM Compound: moxifloxacin	Cytotoxicity against human Hep2 laryngeal carcinoma cell line Cytotoxicity against human Hep2 laryngeal carcinoma cell line	[PMID: 16337791]
HeLa	IC₅₀	110 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	320 μM Compound: Moxifloxacin	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
HeLa	IC₅₀	320 μg/mL Compound: Moxifloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HepG2	CC₅₀	> 100 μM Compound: MXF	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	EC₅₀	> 100 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay	[PMID: 33929852]
HepG2	IC₅₀	> 50 μM Compound: Moxifloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 35500229]
Hepatocyte	CC₅₀	> 100 μM Compound: MXF	Cytotoxicity against rat hepatocytes after 48 hrs Cytotoxicity against rat hepatocytes after 48 hrs	[PMID: 17228862]
J774.A1	IC₅₀	14.56 μg/mL Compound: MOX	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	[PMID: 35486992]
K562	EC₅₀	> 100 μM Compound: 2	Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay	[PMID: 33929852]
L6	IC₅₀	5.7783 μM Compound: Moxifloxacin	Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay	[PMID: 32623216]
MDCK	CC₅₀	161 μM Compound: MXFX	Cytotoxicity against MDCK cells after 48 hrs by CPE assay Cytotoxicity against MDCK cells after 48 hrs by CPE assay	[PMID: 21481984]
MG-63	IC₅₀	170 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	230 μM Compound: Moxifloxacin	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MG-63	IC₅₀	230 μg/mL Compound: Moxifloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MRC5	IC₅₀	10.9 μM Compound: Moxifloxacin (MFLX)	In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii	[PMID: 15125930]
MRC5	IC₅₀	> 100 μg/mL Compound: MOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis	[PMID: 35486992]
NIH3T3	IC₅₀	379.82 μg/mL Compound: Moxifloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	160 μg/mL Compound: Moxifloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	> 400 μg/mL Compound: Moxifloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
THP-1	EC₅₀	5.07 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS	[PMID: 20385862]
THP-1	EC₅₀	5.21 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS	[PMID: 20385862]
THP-1	EC₅₀	8.09 mg/L Compound: Moxifloxacin	Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS	[PMID: 20385862]
Vero	CC₅₀	128 μg/mL Compound: MXF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29227930]
Vero	CC₅₀	128 μg/mL Compound: Moxifloxacin	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	[PMID: 31352245]

体外実験

The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia^[4]
Dosage:	12 mg/kg
Administration:	Intravenous injection; once per day, twice per day, three times per day; for 7 days
Result:	Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.

臨床実験

分子量

401.43

分子式

C₂₁H₂₄FN₃O₄

CAS 番号

151096-09-2

Appearance

Solid

Color

White to yellow

SMILES

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 31.25 mg/mL (77.85 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4911 mL	12.4555 mL	24.9109 mL
5 mM	0.4982 mL	2.4911 mL	4.9822 mL
10 mM	0.2491 mL	1.2455 mL	2.4911 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.75%

Select Batch:

データシート (277 KB) SDS (597 KB)

COA (251 KB) HNMR (265 KB) RP-HPLC (221 KB) MS (69 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88. [Content Brief]

[2]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [Content Brief]

[3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. [Content Brief]

[4]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4911 mL	12.4555 mL	24.9109 mL	62.2774 mL
	5 mM	0.4982 mL	2.4911 mL	4.9822 mL	12.4555 mL
	10 mM	0.2491 mL	1.2455 mL	2.4911 mL	6.2277 mL
	15 mM	0.1661 mL	0.8304 mL	1.6607 mL	4.1518 mL
	20 mM	0.1246 mL	0.6228 mL	1.2455 mL	3.1139 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4911 mL
	30 mM	0.0830 mL	0.4152 mL	0.8304 mL	2.0759 mL
	40 mM	0.0623 mL	0.3114 mL	0.6228 mL	1.5569 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0380 mL

Moxifloxacin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Moxifloxacin151096-09-2BAY 12-8039BacterialAntibioticInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

モキシフロキサシン (Synonyms: Moxifloxacin; BAY 12-8039 (free base))

カスタマーレビュー

Other Forms of Moxifloxacin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Moxifloxacin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

モキシフロキサシン (Synonyms: Moxifloxacin; BAY 12-8039 (free base))

カスタマーレビュー

Other Forms of Moxifloxacin:

モキシフロキサシン 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

モキシフロキサシン 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Moxifloxacin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

モキシフロキサシン関連抗体

モキシフロキサシン関連抗体